Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Difference in the Donor Selection Priority in Allogeneic Hematopoietic Stem Cell Transplantation According to Patient Age

Koji Kawamura, Junya Kanda, MD, Sachiko Seo, MDPhD, Fumihiko Kimura, MD PhD, Masahiro Hirayama, MD PhD, Naoyuki Uchida, MD PhD, Noriko Doki, MD PhD, Takahiro Fukuda, Yukiyasu Ozawa, MD PhD, Yuta Katayama, MD PhD, Minoko Takanashi, MD PhD, Yoshiko Atsuta, MD PhD, Yoshinobu Kanda, MD PhD

Blood (2019) 134 (Supplement_1): 46.

https://doi.org/10.1182/blood-2019-125032

Published: 2019

Journal Articles

Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents

Hiroyuki Takamatsu, MD PhD, Shohei Mizuno, MD PhD, Tsutomu Takahashi, MD PhD, Shin-Ichi Fuchida, MD PhD, Ichiro Hanamura, MD PhD, Fumihiko Nakamura, MD PhD, Takehiko Mori, MD PhD, Yuta Katayama, MD PhD, Noriko Doki, MD PhD, Nobuhiro Tsukada, MD PhD, Tatsuo Ichinohe, Yoshinobu Kanda, MD PhD, Yoshiko Atsuta, MD PhD, Kazutaka Sunami, MD PhD

Blood (2019) 134 (Supplement_1): 4358.

https://doi.org/10.1182/blood-2019-123607

Published: 2019

Journal Articles

Impact of Different Doses of Fludarabine in Fludarabine-Based Conditioning Regimen for Unrelated Bone Marrow Transplantation

Kodai Kuriyama, MD PhD, Shigeo Fuji, MD PhD, Noriko Doki, MD PhD, Yuta Katayama, MD PhD, Souichi Shiratori, Yukiyasu Ozawa, MD PhD, Takashi Ashida, MD PhD, Junya Kanda, MD, Takahiro Fukuda, Yoshiko Atsuta, MD PhD, Masao Ogata, MD PhD

Blood (2019) 134 (Supplement_1): 3258.

https://doi.org/10.1182/blood-2019-123926

Published: 2019

Journal Articles

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Tsuyoshi Muta, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Yoshimasa Suetsugu, MD, Masaaki Noda, MD, Tasuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Tatsuji Mino, Ryota Imanaka, MD, Kohei Kyo, MD, Yuta Katayama, MD PhD, Shinya Katsutani, MD PhD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 5321.

https://doi.org/10.1182/blood-2018-99-116016

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis

Tatsuji Mino, Yuta Katayama, MD PhD, Tatsuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Takeshi Okatani, MD, Ryota Imanaka, MD, Kohei Kyo, MD, Mitsuhiro Itagaki, MD, Shinya Katsutani, MD PhD, Tsuyoshi Muta, MD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 2095.

https://doi.org/10.1182/blood-2018-99-113461

Published: 2018

Journal Articles

Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center Study in Japan

Blood (2015) 126 (23): 4341.

https://doi.org/10.1182/blood.V126.23.4341.4341

Published: 2015

Journal Articles

Therapy for AML with Myelodysplasia-Related Changes (AML-MRC)

Taiichi Kyo, MD, Kouhei Kyo, MD, Takeshi Okatani, MD, Tetsuro Ochi, MD, Kayo Toishigawa, Ryota Imanaka, MD, Yuta Katayama, MD PhD, Mitsuhiro Itagaki, MD

Blood (2015) 126 (23): 1340.

https://doi.org/10.1182/blood.V126.23.1340.1340

Published: 2015

Journal Articles

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Ryota Imanaka, MD, Taiichi Kyo, MD, Kayo Toishigawa, MD, Tetsuro Ochi, MD, Takeshi Okatani, MD, Kouhei Kyo, MD, Mitsuhiro Itagaki, MD, Hisao Nagoshi, MD, Yuta Katayama, MD PhD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2015) 126 (23): 2500.

https://doi.org/10.1182/blood.V126.23.2500.2500

Published: 2015

Journal Articles

Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation

Kazuyoshi Ishii, MD MPH, PhD, Shosaku Nomura, MD PhD, Tomoki Ito, MD PhD, Yuta Katayama, MD PhD, Taiichi Kyo, MD, Shuichi Ota, MD PhD, Masanori Seki, MD PhD, Shigeru Chiba, MD PhD, Yoshinobu Maeda, MD PhD, Mitsune Tanimoto, MD PhD, Takayuki Ikezoe, MD PhD, Hideo Yagi, MD PhD, Yoji Ishida, MD, PhD, Naohito Fujishima, MD PhD, Kenichi Sawada, MDPhD

Blood (2014) 124 (21): 5089.

https://doi.org/10.1182/blood.V124.21.5089.5089

Published: 2014

Journal Articles

Recombinant Thrombomodurin For The Treatment Of Transplantation-Associated Coagulopathy After Allogeneic Stem Cell Transplantation

Kazuyoshi Ishii, MD, MPH, PhD, Shosaku Nomura, MD, PhD, Tomoki Ito, MD, PhD, Yuta Katayama, MD, PhD, Taiichi Kyo, MD, Shuichi Ota, MD, PhD, Masanori Seki, MD, PhD, Shigeru Chiba, MD, PhD, Yoshinobu Maeda, M.D., Ph.D., Mitsune Tanimoto, MD, PhD, Takayuki Ikezoe, MD. PhD, Hideo Yagi, MD, PhD, Yoji Ishida, M.D., Ph.D., Naohito Fujishima, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2013) 122 (21): 5454.

https://doi.org/10.1182/blood.V122.21.5454.5454

Published: 2013

Journal Articles

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Taiichi Kyo, M.D., Kouhei Kyo, MD, Ryouta Imanaka, M.D., Mitsuhiro Itagaki, MD, Tetsuro Ochi, Takeshi Okatani, M.D., Koji Iwato, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 1571.

https://doi.org/10.1182/blood.V122.21.1571.1571

Published: 2013

Journal Articles

Voriconazole (VRCZ) Versus Itraconazole (ITCZ) As Antifungal Prophylaxis For Acute Myelogenus Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients In Induction Therapy, Prospective Randomized Study

Kouhei Kyo, M.D., Mitsuhiro Itagaki, MD, Taiichi Kyo, MD, Takeshi Okatani, M.D., Tetsuro Ochi, Yuta Katayama, MD, PhD, Ryouta Imanaka, M.D., Kouji Iwato, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 3897.

https://doi.org/10.1182/blood.V122.21.3897.3897

Published: 2013

Journal Articles

Levels of sIL-2R in Sera Depend On Number of CD25-Positive Lymphoma Cells and MMP-9-Positive Macrophages in DLBCL.

Noriaki Yoshida, MD, Akira Sakai, MD, PhD, Yoshiko Okikawa, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, MD, Hirotaka Matsui, MD, PhD, Koji Arihiro, MD, PhD, Megumu Fujihara, MD, PhD, Takashi Nishisaka, MD, PhD, Naomi Sasaki, MD, PhD, Yoshito Sadahira, MD, PhD, Akiro Kimura, MD, PhD

Blood (2009) 114 (22): 2927.

https://doi.org/10.1182/blood.V114.22.2927.2927

Published: 2009

NARROW

Difference in the Donor Selection Priority in Allogeneic Hematopoietic Stem Cell Transplantation According to Patient Age

Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents

Impact of Different Doses of Fludarabine in Fludarabine-Based Conditioning Regimen for Unrelated Bone Marrow Transplantation

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis

Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center Study in Japan

Therapy for AML with Myelodysplasia-Related Changes (AML-MRC)

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation

Recombinant Thrombomodurin For The Treatment Of Transplantation-Associated Coagulopathy After Allogeneic Stem Cell Transplantation

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Voriconazole (VRCZ) Versus Itraconazole (ITCZ) As Antifungal Prophylaxis For Acute Myelogenus Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients In Induction Therapy, Prospective Randomized Study

Levels of sIL-2R in Sera Depend On Number of CD25-Positive Lymphoma Cells and MMP-9-Positive Macrophages in DLBCL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only